

Ref: SEC/SE/2015-16  
Date: 25.08.2015



To,  
Corporate Relation Department  
Bombay Stock Exchange Ltd.  
1<sup>st</sup> Floor, Rotunda Building  
Dalal Street,  
**Mumbai – 400 001.**

**Re: Clarification/ confirmation on news item appearing in “CNBC TV 18”**

Dear Sir,

This is with reference to your email referring to news item which appeared in CNBC TV 18 dated August 25, 2015 captioned “USA FDA issues import alert to Dabur’s Alwar Unit” and further that the price of the Company scrip decreased by 5.83% on date August 25, 2015 moving from Rs. 273.19 to Rs.257.25.

With respect to the above we wish to inform the following:

- US FDA had not put any restriction on import and sale in the US, of products manufactured at Dabur’s Alwar unit. The US FDA has, however, sought some additional information and we are in the process of submitting the same. This is a routine procedural matter and will not impact our business in the US.
- The aforesaid news item have no material impact on Dabur India Limited.
- Decrease in the share price of the Company by 5.83% (moving from Rs. 273.19 to Rs.257.25) is market driven and the aforesaid news item has no significant bearing on the same.

Thanking you,

Yours faithfully  
For Dabur India Limited

  
(A.K. Jain)  
V P (Finance) and Company Secretary

Copy to:

Metropolitan Stock Exchange Limited (mSXI)  
4<sup>th</sup> Floor, Vibgyor Towers, Plot No. C-62, G-Block, Opposite Trident Hotel, Bandra Kurla  
Complex, Bandra (E), Mumbai – 400098